In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon β-1a

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 984-996

  Hu, Xiao ^a   Olivier, Kenneth ^a,b   Polack, Evelyne ^a   Crossman, Mary ^a   Zokowski, Katie ^a   Gronke, Robert S ^a   Parker, Suezanne ^a   Li, Zhaoyang ^a,c   Nestorov, Ivan ^a   Baker, Darren P ^a   Clarke, Janet ^a   Subramanyam, Meena ^a  

^a BIOGEN   (United States)

^b MERRIMACK PHARMACEUTICALS   (United States)

^c Sanofi Aventis US LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON; MACROGOL; NEOPTERIN; NEUTRALIZING ANTIBODY; PEGINTERFERON BETA1A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FEVER; GOOD LABORATORY PRACTICE; IMMUNOGENICITY; IN VIVO STUDY; LEUKOCYTOSIS; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY TEMPERATURE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEEDBACK, PHYSIOLOGICAL; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERONS; LYMPHOCYTE COUNT; MACACA MULATTA; MODELS, STATISTICAL; NEOPTERIN; NO-OBSERVED-ADVERSE-EFFECT LEVEL; POLYETHYLENE GLYCOLS;

EID: 80052173934     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180661     Document Type: Article

References (33)

1. Arduini RM, Li Z, Rapoza A, Gronke R, Hess DM, Wen D, Miatkowski K, Coots C, Kaffashan A, Viseux N, et al. (2004) Expression, purification, and characterization of rat interferon-β, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif 34:229-242. (Pubitemid 38390571)
2. Axtell RC and Steinman L (2008) Type 1 interferons cool the inflamed brain. Immunity 28:600-602. (Pubitemid 351636249)
3. Bailon P and Won CY (2009) PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6:1-16.
4. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, et al. (2006) N-terminally PEGylated human interferon-β-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 17:179-188. (Pubitemid 43157600)
5. Baker DP, Pepinsky RB, Brickelmaier M, Gronke RS, Hu X, Olivier K, Lerner M, Miller L, Crossman M, Nestorov I, et al. (2010) PEGylated interferon β-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res 30:777-785.
6. Bauer RJ (2009) NONMEM User's Guide: Introduction to NONMEM 7, Icon Development Solutions, Ellicott City, MD.
7. Beal SL, Sheiner LB, and Boechmann AJ (1989-2006) NONMEM User's Guide, Icon Development Solutions, Ellicott City, MD.
8. Bino T, Edery H, Gertler A, and Rosenberg H (1982a) Involvement of the kidney in catabolism of human leukocyte interferon. J Gen Virol 59:39-45.
9. Bino T, Madar Z, Gertler A, and Rosenberg H (1982b) The kidney is the main site of interferon degradation. J Interferon Res 2:301-308. (Pubitemid 13138655)
10. 125I-interferon α in lysosomes of rabbit proximal tubule cells. J Submicrosc Cytol 16:753-757.
11. Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, Santiano M, and Viano I (1981) Renal filtration, absorption and catabolism of human α interferon. J Interferon Res 1:347-352. (Pubitemid 12105785)
12. Cutrone EC and Langer JA (1997) Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett 404:197-202. (Pubitemid 27113452)
13. Coyle PK (2008) Switching algorithms: from one immunomodulatory agent to another. J Neurol 255(Suppl 1):44-50.
14. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478. (Pubitemid 24025269)
15. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, et al. (2011) A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol doi: 10.1177/0091270011407068.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
17. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. (1996) Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294.
18. Karpusas M, Whitty A, Runkel L, and Hochman P (1998) The structure of human interferon-β: implications for activity. Cell Mol Life Sci 54:1203-1216. (Pubitemid 28529112)
19. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39:D1035-D1041.
20. Liberati AM, Fizzotti M, Proietti MG, Di Marzio R, Schippa M, Biscottini B, Senatore M, Berruto P, Canali S, and Peretti G (1988) Biochemical host response to interferon-β. J Interferon Res 8:765-777.
21. Lugaresi A (2009) Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 6:995-1002.
22. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-β1a in humans. Pharm Res 19:1537-1543. (Pubitemid 35266560)
23. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, and Jusko WJ (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a in monkeys. J Pharmacol Exp Ther 306:262-270.
24. Mager DE, Neuteboom B, and Jusko WJ (2005) Pharmacokinetics and pharmacodynamics of PEGylated IFN-β 1a following subcutaneous administration in monkeys. Pharm Res 22:58-61. (Pubitemid 40558146)
25. Martin PL, Vaidyanathan S, Lane J, Rogge M, Gillette N, Niggemann B, and Green J (2002) Safety and systemic absorption of pulmonary delivered human IFN-β1a in the nonhuman primate: comparison with subcutaneous dosing. J Interferon Cytokine Res 22:709-717. (Pubitemid 35034531)
26. Mohr DC, Boudewyn AC, Likosky W, Levine E, and Goodkin DE (2001) Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23:125-132. (Pubitemid 32488430)
27. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group, et al. (2002) Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506. (Pubitemid 35387053)
28. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, and Martin P (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297:1059-1066. (Pubitemid 32472504)
29. Pestka S, Langer JA, Zoon KC, and Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56:727-777. (Pubitemid 17105465)
30. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504.
31. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, and Biollaz J (1999) Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141. (Pubitemid 29488578)
32. Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, and Whitty A (2000) Systematic mutational mapping of sites on human interferon-β-1a that are important for receptor binding and functional activity. Biochemistry 39:2538-2551. (Pubitemid 30148906)
33. Savic RM, Jonker DM, Kerbusch T, and Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726. (Pubitemid 47477040)